Category: Joint ventures/collaborations
-
Cancer Centers, Analytics, Pharma Plan Precision Medicine
7 April 2016. A cancer care center network, with pharmaceutical and informatics companies, plan to apply precision medicine techniques to increase the pool of patients for clinical trials of new cancer therapies. The coalition includes cancer centers in the Orien network — short for Oncology Research Information Exchange Network — with bioinformatics company M2Gen, and…
-
Intrexon Spin-Off Developing Type 1 Diabetes Therapy
4 April 2016. A new subsidiary of the synthetic biology company Intrexon Corp. is creating a pill for people with type 1 diabetes to stop the disease’s damage in its early stages. The enterprise, known as Intrexon T1D Partners LLC, is a joint venture between Intrexon, in Germantown, Maryland, and White Rock Capital Partners a…
-
Foundation Supporting ALS Progression Model Study
31 March 2016. A study to validate computer models that predict progression and survival of patients with ALS is underway by a bioinformatics company and biopharmaceutical developer. The 3-year project is funded by a grant of nearly $500,000 from ALS Association in Washington, D.C. ALS, or amyotrophic lateral sclerosis, also known as Lou Gehrig’s disease,…
-
Regeneron, Bayer Collaborating on Eye Disorder Drug
24 March 2016. Regeneron Pharmaceuticals and drug-maker Bayer AG are developing a combination of biologic drugs to treat the eye disorders wet age-related macular degeneration and diabetic macular edema. The agreement — the third such deal between the companies — is expected to bring Regeneron as much as $130 million if all milestones are met.…
-
Propeller, Boehringer Partner on Inhaler Adherence Study
23 March 2016. The pharmaceutical company Boehringer Ingelheim is collaborating with a mobile health technology developer to track use of its medications for asthma and COPD administered with its inhaler. Financial aspects of the agreement between Propeller Health in Madison, Wisconsin, and Boehringer Ingelheim were not disclosed. Boehringer Ingelheim, headquartered in Germany, markets a number…
-
Nanoparticles Shown to Target Tumors, Avoid Adjacent Cells
22 March 2016. A small-scale clinical trial shows cancer drugs formulated into nanoparticles accumulate in solid tumors in humans, while avoiding adjacent healthy tissue. The team from California Institute of Technology in Pasadena published its findings yesterday (21 March) in the journal Proceedings of the National Academy of Sciences. The CalTech team, led by chemical engineering…
-
Merck Licensing Harvard Cancer Drug Molecules
21 March 2016. The pharmaceutical company Merck is licensing small molecule research discoveries from a Harvard University lab as potential treatments for leukemia. The agreement brings the university $20 million immediately, with further payments expected as Merck develops the discoveries into products. The deal gives Merck an exclusive license to research by biochemistry professor Matthew…
-
Allied-Bristol Licenses NYU Research, Starts New Company
17 March 2016. Allied-Bristol Life Sciences, a joint venture of Allied Minds and Bristol-Myers Squibb, is licensing research from New York University on signaling pathways affecting growth of tumors, for a new company begun under its tutelage. Financial aspects of the deal between Allied-Bristol and NYU were not disclosed. The new enterprise, known as iBeCa…
-
Roche Licensing Biotech Immunotherapies in $1B Deal
15 March 2016. The biotechnology company Blueprint Medicines, a developer of cancer treatments based on a patient’s precise genomic make-up, is partnering with the pharmaceutical company Roche on cancer immunotherapies. The agreement gives Roche options to license up to 5 small-molecule, or low molecular-weight therapies, in a deal that could bring Blueprint more than $1…
-
FDA Gives Initial Clearance for Engineered Mosquitoes
11 March 2016. The U.S. Food and Drug Administration issued a preliminary report that self-limiting engineered mosquitoes will have no significant environmental impacts on the Florida Keys, where they plan to be tested. The report agrees with an environmental assessment by Oxitec Ltd., developer of the engineered mosquitoes, that the agency is releasing for public…